Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Hypersensitivity Reaction

  Free Subscription


Articles published in Eur J Dermatol

Retrieve available abstracts of 55 articles:
HTML format



Single Articles


    February 2022
  1. VAN HALEWIJN KF, Lahnstein T, Bohnen AM, Van Den Berg PJ, et al
    Recommendations for emollients, bathing and topical corticosteroids for the treatment of atopic dermatitis: a systematic review of guidelines.
    Eur J Dermatol. 2022 Feb 21. pii: ejd.2022.4197. doi: 10.1684/ejd.2022.4197.
    PubMed     Abstract available


  2. NADA HR, Rashed LA, Shehada J, Mostafa PIN, et al
    Phosphodiesterase 4 (PDE4) gene expression in atopic dermatitis patients, before and after treatment with topical mometasone cream.
    Eur J Dermatol. 2022 Feb 15. pii: ejd.2022.4194. doi: 10.1684/ejd.2022.4194.
    PubMed     Abstract available


  3. ESCURE G, Nudel M, Terriou L, Farhat MM, et al
    Tolerance of bradykinin-releasing drugs in patients with acquired C1 inhibitor deficiency: a case series and review of the literature.
    Eur J Dermatol. 2022;32:49-55.
    PubMed    


    January 2022
  4. LEFEVRE MA, Mosnier A
    A case of paracetamol-induced nonpigmented fixed drug eruption confirmed by a lymphocyte transformation test.
    Eur J Dermatol. 2022;32:154-156.
    PubMed    


  5. SHEN X, Zhang W, Li X, Lu H, et al
    Association between serum IgG and Henoch-Schonlein purpura with renal involvement in children: a cross-sectional study.
    Eur J Dermatol. 2022;32:132-134.
    PubMed    


    December 2021
  6. SALAVA A, Perala M, Juppo M, Pelkonen AS, et al
    Effective treatment of atopic dermatitis in small children significantly improves the quality of life of patients and their families.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4169. doi: 10.1684/ejd.2021.4169.
    PubMed     Abstract available


  7. EGEBERG A, Anderson P, Piercy J, Massey L, et al
    Symptom burden of patients with moderate-to-severe atopic dermatitis.
    Eur J Dermatol. 2021 Dec 21. pii: ejd.2021.4166. doi: 10.1684/ejd.2021.4166.
    PubMed     Abstract available


  8. LORET L, Ninclaus V, Dendooven A, Lapeere H, et al
    Canalicular stenosis associated with dupilumab treatment for atopic dermatitis.
    Eur J Dermatol. 2021 Dec 17. pii: ejd.2021.4180. doi: 10.1684/ejd.2021.4180.
    PubMed    


  9. CHESTER J, Kaleci S, Liberati S, Alicandro T, et al
    Atopic dermatitis associated with autoimmune, cardiovascular and mental health comorbidities: a systematic review and meta-analysis.
    Eur J Dermatol. 2021 Dec 15. pii: ejd.2021.4168. doi: 10.1684/ejd.2021.4168.
    PubMed     Abstract available


  10. LEFEVRE MA, Mohme S, Alband N, Nogueira M, et al
    Journal club: New small molecules for atopic dermatitis management.
    Eur J Dermatol. 2021;31:849-852.
    PubMed    


  11. TRAIDL S, Heratizadeh A, Werfel T, Dressler C, et al
    Online survey to identify current challenges in atopic dermatitis management and guideline implementation in German-speaking countries.
    Eur J Dermatol. 2021;31:806-812.
    PubMed     Abstract available


  12. ROVATI C, Rossi M, Gelmetti A, Tomasi C, et al
    Impact of the COVID-19 pandemic and lockdown on the clinical response to dupilumab treatment and the psychological status of non-infected atopic patients.
    Eur J Dermatol. 2021;31:736-740.
    PubMed     Abstract available


  13. RAVAL NS, Snowden CK, De Monnin KS, Yokoyama CC, et al
    Scarring alopecia developing after mogamulizumab-associated rash.
    Eur J Dermatol. 2021;31:841-843.
    PubMed    


  14. SUKAKUL T, Svedman C, Dahlin J, Bergendorff O, et al
    Simultaneous positive patch test reactions to neomycin and low-molecular-weight heparins: possible cross-reaction?
    Eur J Dermatol. 2021;31:741-743.
    PubMed     Abstract available


    October 2021
  15. KURIHARA K, Fujiyama T, Tokura Y, Honda T, et al
    Two cases of psoriasiform dermatitis arising during dupilumab therapy and successfully treated with delgocitinib ointment.
    Eur J Dermatol. 2021 Oct 26. pii: ejd.2021.4140. doi: 10.1684/ejd.2021.4140.
    PubMed    


  16. KHELLAF L, Cosserat J, Calas A, Brasme H, et al
    Unusual neurological and cardiac complications of drug reaction with eosinophilia and systemic symptoms syndrome: a case report.
    Eur J Dermatol. 2021;31:652-654.
    PubMed    


  17. FANG YH, Wei KC, Yu MS
    Improvement of erythema elevatum diutinum refractory to dapsone following treatment for underlying multiple myeloma.
    Eur J Dermatol. 2021;31:655-657.
    PubMed    


    August 2021
  18. ASANO A, Nakai K, Hayashi D, Hashimoto T, et al
    A case of delgocitinib-indued anti-LAD-1 IgG-positive, anti-BP180 NC16A IgG-negative bullous pemphigoid in a patient with atopic dermatitis.
    Eur J Dermatol. 2021 Aug 17. pii: ejd.2021.4105. doi: 10.1684/ejd.2021.4105.
    PubMed    


  19. INGEN-HOUSZ-ORO S, Staumont-Salle D, Palladini A, Ferries L, et al
    Immunosuppressants as steroid-sparing agents for chronic DRESS: four cases.
    Eur J Dermatol. 2021;31:576-577.
    PubMed    


    June 2021
  20. ZHANG Z, Li H, Zhang H, Cheng R, et al
    Factors associated with persistence of early-onset atopic dermatitis up to the age of 12 years: a prospective cohort study in China.
    Eur J Dermatol. 2021;31:403-408.
    PubMed     Abstract available


  21. LEFEVRE MA, Nosbaum A
    Dermpath and Clinic: How to manage adverse reactions to biological agents.
    Eur J Dermatol. 2021;31:426-427.
    PubMed    


  22. CUI Y, Shi J, Wang C, Vinturache A, et al
    Therapeutic plasma exchange combined with continuous venovenous hemofiltration in a series of pediatric patients with toxic epidermal necrolysis.
    Eur J Dermatol. 2021;31:413-415.
    PubMed    


  23. WATABE D, Amano H
    TNF-alpha inhibitor-induced paradoxical psoriasis and erythema nodosum in a patient with ankylosing spondylitis.
    Eur J Dermatol. 2021;31:412-413.
    PubMed    


  24. PERRON E, Viarnaud A, Marciano L, Karkouche R, et al
    Clinical and histological features of fixed drug eruption: a single-centre series of 73 cases with comparison between bullous and non-bullous forms.
    Eur J Dermatol. 2021;31:372-380.
    PubMed     Abstract available


  25. SUGINO H, Nakamura M
    Mild hypertrichosis in both upper arms around dupilumab injection sites.
    Eur J Dermatol. 2021;31:420-421.
    PubMed    


    April 2021
  26. SUN J, Gu Y, Li K, Zhang JZ, et al
    Co-existence of specific IgE antibodies and T cells reactive to house dust mites and human transglutaminase3/tropomysin in patients with atopic dermatitis.
    Eur J Dermatol. 2021 Apr 16. pii: ejd.2021.4018. doi: 10.1684/ejd.2021.4018.
    PubMed     Abstract available


  27. MICHELOTTI A, Cestone E, De Ponti I, Giardina S, et al
    Efficacy of a probiotic supplement in patients with atopic dermatitis: a randomized, double-blind, placebo-controlled clinical trial.
    Eur J Dermatol. 2021 Apr 16. pii: ejd.2021.4019. doi: 10.1684/ejd.2021.4019.
    PubMed     Abstract available


  28. PINO LOPEZ J, Kromer C, Herr R, Schmieder A, et al
    Drug survival rates and reasons for drug discontinuation in patients with atopic dermatitis: a retrospective study of adult outpatients.
    Eur J Dermatol. 2021 Apr 16. pii: ejd.2021.4020. doi: 10.1684/ejd.2021.4020.
    PubMed     Abstract available


  29. PAN C, Cheng R, Li Y, Zhao M, et al
    Deep-intronic and frameshift DSG1 variants associated with atypical severe dermatitis, multiple allergies and metabolic wasting (SAM) syndrome in a Chinese family.
    Eur J Dermatol. 2021 Apr 5. pii: ejd.2021.4012. doi: 10.1684/ejd.2021.4012.
    PubMed     Abstract available


  30. MORIMOTO H, Fukuchi K, Ogura Y, Ohtsuka M, et al
    Development of lichen planus following benralizumab treatment.
    Eur J Dermatol. 2021 Apr 2. pii: ejd.2021.3995. doi: 10.1684/ejd.2021.3995.
    PubMed    


  31. GIORDANO-LABADIE F, Becherel PA, Pralong P, Outtas O, et al
    Improvement of patient outcomes following therapeutic optimization of chronic urticaria: two-year data from France as part of the international real-life AWARE study.
    Eur J Dermatol. 2021;31:217-224.
    PubMed     Abstract available


    March 2021
  32. KIRSTEN N, Mohr N, Maul JT, Augustin M, et al
    Incidence of atopic conditions in people with psoriasis: a population-based analysis.
    Eur J Dermatol. 2021 Mar 1. pii: ejd.2021.3963. doi: 10.1684/ejd.2021.3963.
    PubMed     Abstract available


    February 2021
  33. BELBEZIER A, Boccon-Gibod I, Bouillet L
    Efficacy of omalizumab for extracutaneous symptoms of chronic spontaneous urticaria.
    Eur J Dermatol. 2021;31:86-87.
    PubMed    


  34. KOMATSU-FUJII T, Ogawa M, Nonoyama S, Fukumoto T, et al
    Recurrence of nivolumab-induced Stevens-Johnson syndrome due to tegafur/gimeracil/oteracil (TS-1(R)) after nivolumab discontinuation.
    Eur J Dermatol. 2021;31:98-99.
    PubMed    


  35. KUMANO Y, Nagai A, Sugiura K
    Erythro-papular type drug eruption caused by fosravuconazole L-lysine ethanolate.
    Eur J Dermatol. 2021;31:90-91.
    PubMed    


  36. UGAJIN T, Namiki T, Yokozeki H
    A case of prurigo caused by hair dye containing p-phenylenediamine: histopathological findings.
    Eur J Dermatol. 2021;31:103-104.
    PubMed    


  37. MAKIHARA-INUKAI M, Takeichi T, Ogawa-Momohara M, Muro Y, et al
    Morphea in a Crohn's disease patient undergoing ustekinumab treatment.
    Eur J Dermatol. 2021;31:96-97.
    PubMed    


  38. FAUCON C, Bernigaud C, Sbidian E, Hue S, et al
    Essential oils as potential triggers for bullous pemphigoid? A report of two patients.
    Eur J Dermatol. 2021;31:92-93.
    PubMed    


  39. HAYAMA K, Fujita H, Asai-Sato M, Kawana K, et al
    Successful treatment of intractable chronic spontaneous urticaria with omalizumab in a patient with ovarian cancer.
    Eur J Dermatol. 2021;31:100-101.
    PubMed    


    January 2021
  40. NAKAGAWA M, Hanada M, Inomata N, Amano H, et al
    A case of a gibberellin-regulated protein-positive patient allergic to various fruits.
    Eur J Dermatol. 2021 Jan 25. pii: ejd.2020.3949. doi: 10.1684/ejd.2020.3949.
    PubMed    


  41. NAGASAWA Y, Iinuma S, Fujii M, Kanno K, et al
    Dasatinib-induced panniculitis in a patient with chronic myeloid leukaemia.
    Eur J Dermatol. 2021 Jan 25. pii: ejd.2020.3946. doi: 10.1684/ejd.2020.3946.
    PubMed    


  42. COSTEDOAT I, Vergara R, Dousset L, Gerard E, et al
    Drug-induced bullous lichenoid eruption: a side effect of nivolumab triggered by the TLR agonist imiquimod.
    Eur J Dermatol. 2021 Jan 15. pii: ejd.2020.3951. doi: 10.1684/ejd.2020.3951.
    PubMed    


    December 2020
  43. DANSET M, Hacard F, Jaulent C, Nosbaum A, et al
    Brodalumab-associated generalized eczematous eruption in a difficult-to-treat psoriasis patient: management without brodalumab withdrawal.
    Eur J Dermatol. 2020 Dec 18. pii: ejd.2020.3910. doi: 10.1684/ejd.2020.3910.
    PubMed    


  44. VERALDI S, Romagnuolo M, Benzecry V
    Urticaria as a first clinical manifestation of COVID-19.
    Eur J Dermatol. 2020;30:737-738.
    PubMed    


  45. APALLA Z, Sidiropoulos T, Kampouropoulou E, Papageorgiou M, et al
    Real-life, long-term data on efficacy, safety, response and discontinuation patterns of omalizumab in a Greek population with chronic spontaneous urticaria.
    Eur J Dermatol. 2020;30:716-722.
    PubMed     Abstract available


    November 2020
  46. KIMURA R, Sugita K, Yamamoto O
    Successful switching to brodalumab in a patient with severe psoriasis developing ixekizumab-induced eczema.
    Eur J Dermatol. 2020 Nov 24. pii: ejd.2020.3904. doi: 10.1684/ejd.2020.3904.
    PubMed    


    October 2020
  47. PARADISI A, Abeni D, Didona D, Ricci F, et al
    A new case series on etanercept treatment for toxic epidermal necrolysis.
    Eur J Dermatol. 2020 Oct 6. pii: ejd.2020.3883. doi: 10.1684/ejd.2020.3883.
    PubMed     Abstract available


  48. XIONG H, Liu G, Xiao J, Han Y, et al
    Recurrence of Stevens-Johnson syndrome/toxic epidermal necrolysis induced by allopurinol and piroxicam.
    Eur J Dermatol. 2020;30:620-621.
    PubMed    


  49. KROMER C, Schon MP, Mossner R
    Eczematous eruption in patients with psoriasis during risankizumab treatment.
    Eur J Dermatol. 2020;30:599-601.
    PubMed    


    August 2020
  50. KRASTEVA M, Caratas-Perifan M, Kock M, Koch T, et al
    Contact allergy to hair-colouring products: a cosmetovigilance follow-up study by four companies in Europe from 2014 to 2017.
    Eur J Dermatol. 2020;30:377-388.
    PubMed     Abstract available


    June 2020
  51. NAM KH, Park SW, Jung ES, Lee SK, et al
    A case of pityriasis lichenoides et varioliformis acuta after topical application of diphenylcyclopropenone.
    Eur J Dermatol. 2020 Jun 14. pii: ejd.2020.3790. doi: 10.1684/ejd.2020.3790.
    PubMed    


  52. SHIBATA A, Ishiguro Y, Makita S, Yamaga Y, et al
    A systemic form chronic active Epstein-Barr virus infection diagnosed from erythema nodosum-like skin lesions.
    Eur J Dermatol. 2020;30:314-316.
    PubMed    


    April 2020
  53. LIU S, Xu Q, Xu Y, Wang X, et al
    Current status of the management of hereditary angioedema in China: a patient-based, cross-sectional survey.
    Eur J Dermatol. 2020;30:169-176.
    PubMed     Abstract available


  54. SAKAI T, Matsuda-Hirose H, Shimada H, Sugiura K, et al
    Generalized pustular psoriasis-like drug eruption manifested by systemic glucocorticosteroid in a patient without IL36RN mutation or an immunological disorder.
    Eur J Dermatol. 2020;30:183-184.
    PubMed    


    February 2020
  55. YANG F, Chen Z, Chen SA, Zhu Q, et al
    Clinical profile of cutaneous adverse drug reactions: a retrospective study of 1883 hospitalized patients from 2007 to 2016 in Shanghai, China.
    Eur J Dermatol. 2020 Feb 6. pii: ejd.2020.3713. doi: 10.1684/ejd.2020.3713.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Hypersensitivity Reaction is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: